The effect of sedation induced by intravenous diazepam on cerebral glucose metabolic activity was ex amined with [18F]2-fluoro-2-deoxY-D-glucose (FDG) and positron emission tomography (PET) in five patients with probable Alzheimer's disease. Each subject was studied on 2 separate days: on one occasion at rest with eyes patched and ears open, and on the second when sedated with intravenous diazepam titrated to maintain stage II sleep by clinical and EEG criteria. Similar patterns of glucose uptake were observed in both the presence and the absence of sedation, but overall glucose utilization Functional brain imaging requires the coopera tion of the subject to minimize head motion and to permit reproducible study conditions. Even rela tively minor changes in sensory stimulation and motor activity have been shown to cause measur able changes in cerebral metabolism estimated by positron emission tomography (PET) with [18F]2fluoro-2-deoxY-D-glucose (FDG) (Phelps et aI., 1981; Mazziotta et aI., 1982). The degree of subject anxiety may also affect results (Risberg et aI. , 1977; Berent et aI., 1985; Reivich and Alavi, 1985). Con sequently, the examination and analysis of indi viduals studied with severe behavioral and move ment disorders have been impaired. In Alzheimer's
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METHODS
Five right-handed patients (one man, four women; mean age 69 years, range 61-81 years) with probable Alzheimer's disease using NINCDS-ADRDA criteria (McKhann et aI., 1984) were studied. All subjects had a history of gradually progressive intellectual deterioration without clinical evidence of cerebrovascular disease (Ha-chinski ischemic scores of <5) (Hachinski et aI., 1975) or significant depressive symptoms. All were normotensive and had no medical illnesses or history of trauma or drug use that could compromise brain function. Each subject underwent a complete neurological and general medical examination and psychometric testing including the Wechsler Adult Intelligence Scale, the Wechsler Memory Scale, and the Mattis Dementia Scale. In each case serial neuropsychometric examinations had documented con tinued intellectual decline over at least a 6-month period. No focal brain abnormalities were observed by computed tomography.
Informed consent was obtained from subjects and their families, and FDG-PET was performed on 2 separate days from 2 to 7 months apart (mean 4.2 months). On the first occasion, subjects were at rest with eyes patched and ears open with ambient room noise kept to a min imum. On the second, conditions were identical except that intravenous diazepam was administered under the supervision of an anesthesiologist. Accurate reposi tioning was assisted by the performance of a preliminary low-resolution scan. Continuous monitoring by EEG was also performed on three of the subjects during the second scan using international 10-20 electrode placement. EEGs were scored in 30-s epochs for sleep stage and in 4-min epochs for spindle count using standard criteria (Rechtschaff en and Kales, 1968) . Diazepam was titrated to maintain stage II sleep by clinical and/or EEG criteria. At this level subjects were arousable to vigorous tactile stim ulation but not to spoken words, and the blink response to eyelash stimulation was abolished. Diazepam sedation was begun 26-65 min (48 ± 7 min, mean ± SEM) before FDG injection to achieve a stable clinical state and to determine an appropriate maintenance infusion rate.
PET scanning was accomplished using a PCT-4600A three-ring, five-slice scanner (Cyclotron Corporation, Berkeley, CA, U.S.A.) following the administration of 5-10 mCi of 18FDG synthesized using the reaction of acetyl hypoflurite with triacetylglucose in Freon-II (Bida et aI., 1984) . This method results in <5% contamination with 2-deoxy-2-fluoromannose. In each scanning session, a series of four interleaved scans was performed parallel to the canthomeatal line. This results in up to 20 images with 8.0-mm full width at half-maximum (FWHM) slice thickness resolution and 1O.9-mm FWHM in-plane reso lution on the machine axis. Extreme inferior and superior horizontal levels and images of inferior technical quality were excluded from analysis. Serial arterial blood samples were used' to determine FDG and glucose con centrations. Images were reconstructed following attenu ation correction by the standard ellipse method. Local rates of glucose utilization were estimated using a four rate constant model and rate constants determined from normal individuals (Huang et aI., 1980) . Above the level of the cerebellum, the cerebral cortex in each image was outlined and divided into four contig uous regions in each hemisphere, each representing a quarter of the anteroposterior extent of the cortex. Visual cortex was analyzed separately. Homologous regions at each level were then averaged to provide mean values in nine cortical regions. Mean cortical metabolic rate was determined by averaging all cortical regions imaged. For analysis of the basal ganglia, horizontal slices in which these structures were prominent were chosen and rectan gular regions of interest measuring 3.7 mm horizontally and 7.5 mm in the anteroposterior axis were moved to J Cereb Blood Flow Metab, Vol, 7, No.4, 1987 achieve peak values where the caudate, putamen, and thalamus were judged to be.
Glucose metabolic rates were compared using Spearman correlation analysis with diazepam dose and psychometric data.
RESULTS
Our method of diazepam sedation provided a safe, reliable, and relatively constant state of seda tion. The amount of diazepam required and its du ration of action varied widely among subjects and was not a function of differences in patient weight or scanning time. From 13.5 to 53.5 mg of diazepam was used during the procedure (33.1 ± 15.6 mg, mean ± SD), the majority of which was used be fore FDG injection to establish a stable level of se dation. Total diazepam doses ranged from 0.16 to 0.96 mg/kg (0.56 ± 0.30 mg/kg), and rates of diaz epam infusion prior to scanning up to the time scans began varied from 1.7 to 7.5 fLg/kg/min (4.6 ± 2.1 fLg/kg/min). The dose of diazepam necessary to induce sedation before FDG injection was larger than that needed to maintain sedation during the first 30 min of isotope uptake (17.1 ± 10.8 vs. 7.9 ± 3.4 mg) (Table O . In some subjects, diazepam induced intermittent and periodic breathing re quiring adjustment of head position to maintain airway patency. Duration of diazepam action also varied greatly among subjects; most awoke soon after completion of the study, but patient 4 re mained drowsy for 12 h after the last dose of diaz epam.
Clinical monitoring proved reliable in assessing lighter sedation, while EEG was more helpful in de lineating times when sedation was more profound. Neither method, however, was useful in predicting patient arousal. The best results were obtained with a schedule of diazepam administration individual ized for each patient before FDG injection and ad justed if EEG indicated sedation was becoming too profound. In those monitored with EEG, stage II sleep was maintained an average of 73% of the time during the first 20 min following FDG injection (range 40-92 min) and sleep efficiency was 99% (range 98-100%). Drug administration and EEG re sults in a typical patient are shown in Fig. 1 .
At rest, metabolic rates for glucose were lowest in temporoparietal cortex and relatively higher in frontal cortex and basal ganglia (Fig. 2) , similar to previous findings in patients with Alzheimer's dis ease (Ingvar et aI., 1975; Frackowiak et aI., 1981; Benson et aI., 1983; Friedland et aI., 1983; Foster et aI., 1984; Haxby et aI., 1985) . This pattern was un changed with sedation (Fig. 2) , but overall cortical glucose utilization rates were decreased an average of 30% by the administration of diazepam (Table 2) . While the decrease in overall cortical rate did not achieve significance in this small group, there was a close correlation between the dose of diazepam given prior to FDG injection and the decline in glu cose utilization (Spearman's p = 1. 0, P < 0. 05) (Table O . There was no relationship between this decline and the dose of diazepam during the first 30 min after FDG injection (p = 0. 56, p = 0. 26) or during the scan itself (p = 0. 10, p = 0. 84). The amount of metabolic depression also tended to be greater when the glucose metabolism was higher at rest (p = -0. 90, p = 0. 08). There was no apparent relationship between diazepam-induced changes in metabolism and either age (p = 0. 60, p = 0. 48) or severity of dementia as measured by the Mattis De mentia Scale (p = -0. 82, p = 0. 23), and no clear relationship was seen between sleep efficiency or depth and the observed decrease in metabolism.
Rates of glucose metabolism were similarly af fected in the basal ganglia ( Table 2) . Effects of diazepam on regional rates of metabo lism were studied by normalizing values to the average overall cortical metabolism found in each scanning session. Visual inspection of images (Fig.  2) and quantitative analysis verified that no system atic regional variations were induced by diazepam sedation either in cortical regions or in the basal ganglia (Table 3) . Left-right ratios were unchanged, indicating that both hemispheres were affected sim ilarly by diazepam. during diazepam sedation (on the right). A common intensity scale has been used to display the images (A). When these images are normalized to overall cortical glucose metabo lism, no apparent differences in relative regional glucose metabolic rates are noted (b). 
DISCUSSION
Diazepam sedation administered under close su pervision of an anesthesiologist was well tolerated by our subjects. While there were no unexpected untoward events, close clinical monitoring and careful titration of dose are required in view of the wide variability in dose and duration of action. Such variability in diazepam distribution and me tabolism is well recognized (Greenblatt et aI., 1984) , particularly among the aged in whom the drug half-life is prolonged (Petrie and Ban, 1984) . Although respiratory depression was not observed, intermittent airway obstruction and periodic breathing in some patients were aggravated by the constraints on head position placed by the scanner.
Achievement of a uniform state of awareness in all subjects during functional brain imaging is diffi cult to achieve. Even among normals, such proce dures are often accompanied by variable degrees of anxiety (Risberg et aI., 1977; Berent et aI., 1985) , and sensory deprivation during a long procedure may easily result in the subject falling asleep. Thus, even the standard alert, awake, but resting state commonly used in FDG-PET studies is not uni form.
J Cereb Blood Flow Metab, Vol. 7, No.4, 1987 In people with dementia, obtaining uniformity of scan conditions is even more difficult than in normal volunteers. Patient cooperation may be fleeting. Sensory deprivation often leads to in creased disorientation and anxiety. The selection of patients without severe behavior disturbance or psychotic symptoms so that the standard FDG-PET procedure can be accomplished introduces an im portant bias. In our center, PET candidates with behavioral abnormalities undergo a practice session during which the PET procedure is performed with the exception of isotope injection and placement of intravenous and intraarterial lines. Successful com pletion of this practice session helps us to deter mine which patients will be able to cooperate during the actual study. Few patients with severe symptoms are able to cooperate fully during such sessions, and thus most FDG-PET studies by our selves and others have been directed at studying patients with mild symptoms (Foster et aI., 1984; Cutler et aI., 1985) . Patients totally dependent for personal care or requiring institutional placement have not been examined. Diazepam sedation offers an opportunity to study a wider variety of patients with dementia.
Since anxiety has been noted to increase frontal cerebral blood flow (Risberg et aI., 1977) , the rela tive sparing of frontal metabolism seen in Alz heimer's disease (Foster and Chase, 1983) could have been related to anxiety. This now appears un likely. Despite anxiolytic and even sedative doses of diazepam, the pattern of predominant temporo parietal hypometabolism remains unchanged.
Our results indicate that diazepam sedation in duces no major differences in relative regional rates of glucose metabolism at the current level of sensi tivity of FDG-PET. This finding is potentially helpful since relative regional values are more sen sitive indicators of Alzheimer's disease than overall average rates (Cutler et aI., 1985) , which have wide intersubject variability (Duara et aI., 1983; Reivich et aI., 1983) .
The results of the present study do not neces- sarily apply to all disease states. U sing an animal model and the [14C]deoxyglucose method, Frey and Agranoff (1983) have shown that anesthetic doses of diazepam depress glucose metabolism more in areas of gliosis than in normal tissue. Thus, diaz epam, especially in more than sedative doses, might produce differing effects on regional glucose metabolism in disorders accompanied by extensive gliotic change, unlike the situation in Alzheimer's disease in which gliosis is not prominent (Corsellis, 1976) . Little change of overall glucose metabolism in re sponse to diazepam was seen in patients 2 and 3. This may be due to the lower doses of diazepam they received as compared with the other subjects. Alternatively, these results may reflect individual differences in response to diazepam or in the slow wave sleep that it induces. Individual variability of cerebral metabolism in unmedicated sleep has pre viously been noted. When cerebral oxygen metabo lism in slow wave sleep was measured using the Kety-Schmidt technique in six healthy young men, five showed a decline in cerebral oxygen consump tion while in the other it actually increased by 34% (Mangold et aI., 1955) .
It is not surprising that the diazepam dose given before the FDG injection, but not the dose given later in the study, correlates closely with the degree of induced depression of overall cortical metabo lism. The majority of FDG is trapped in the first 10 min, and thus the amount of diazepam present ini tially is likely to have the greatest influence on the results. Previous studies performed on dogs have found that maximal depression of cerebral metabo lism after an intravenous injection of diazepam occurs at 10 min and significant reductions remain noticeable for 90 min (Sari et aI., 1975) . Conse quently, it is the diazepam given before the scan that has the predominant influence on cerebral glu cose metabolism. With increasing time, additional diazepam has less effect, but the extent of depres sion observed in our cases suggests that no matter what the time of use, diazepam may affect esti mates of global glucose metabolism and only rela tive metabolism or metabolic asymmetries can be estimated reliably.
The generalized decline of glucose metabolism observed in this study may be due either to the sleep state itself or to the effects of diazepam. Studies comparing local cerebral metabolism during wakefulness and slow wave sleep have shown nonselective declines of 30% in rhesus monkeys (Kennedy et aI., 1982) and 12.5% in young healthy men without altering the regional pattern of metabolism (Heiss et aI., 1985) . Similar changes in regional cerebral blood flow are seen. Progressive reduction in regional cerebral blood flow of from 6 to 14% throughout the cerebrum has been noted with progressively deeper sleep in young healthy men, as shown with xenon-133 (Townsend et aI., 1973; Sakai et aI., 1980) . While disagreements remain as to whether small subcor tical and brainstem nuclei are all similarly affected during slow wave sleep (Nakamura et aI., 1983; Ramm and Frost, 1983) , these structures are below the resolving power of current FDG-PET methods.
Diazepam and other benzodiazepines decrease cerebral glucose metabolism (Rockoff et aI., 1980; Oguchi et aI., 1982) and blood flow (Forster et aI., 1982) . Although it has not yet been clearly demon strated, the decrease in glucose metabolism in duced by diazepam, like its sedative effects, might be expected to be dose related. The present results in which the diazepam dose given prior to FDG in jection correlated with the observed decline in average glucose utilization are consistent with this notion. The results do not appear to be related to disease progression or habituation (order) effect. Patient 5 was given a third scan at rest 9 months following her initial study. Overall metabolic values were essentially unchanged from the baseline study (unpublished data). Furthermore, the magnitude of the change caused by diazepam sedation is larger than the difference observed between mild and se vere Alzheimer's patients and seems unlikely to be explained by progression of the disease over only 4 months. Thus, it appears likely that both diazepam and sleep stage contributed to the observed de clines in cerebral glucose metabolism seen in our patients sedated with diazepam.
